By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

PIQUR Therapeutics AG 

Hochbergerstrasse 60C

Basel    CH-4057  Switzerland
Phone: 41-61-633-29-29 Fax: n/a


SEARCH JOBS

PIQUR was founded in August 2011 by Vladimir Cmiljanovic, Bernd Giese, Matthias Wymann, Andreas Emmenegger and Ralf Rosenow as a spin-off of the University of Basel. The company focuses on the discovery and development of innovative anti-cancer drugs based on the inhibition of the PI3K (phosphoinositide 3-kinase) and mTOR (mammalian target of rapamycin) pathways, one of the most promising research areas in oncology and clinically validated drug targets. PIQUR’s lead candidate, PQR309, has successfully concluded the first Phase 1 trial. The initial results indicate that PQR309 is well-tolerated with no significant side effects and meets the primary endpoints of safety and tolerability. Furthermore, PQR309 demonstrated clear biologic activity and first promising signs of clinical activity. In Q2/2015, PIQUR has started Phase 2 trials with PQR309 in selected cancer indications.

YEAR FOUNDED:

August 2011

LEADERSHIP:

CEO: Vladimir Cmiljanovic

CMO:Melanie Rolli

CSO: Doriano Fabbro

CBO: Hervé Girsault

CFO: Martin Gasser

JOBS:

Please click here for PIQUR job opportunities.

CLINICAL TRIAL:

Please click here for clinical trial information.


Key Statistics


Email: info@piqur.com
Ownership: Private

Web Site: PIQUR Therapeutics AG
Employees:
Symbol: 
 



Industry
Biotechnology






Company News
//-->